Chantix might not increase heart risk, review shows

Pfizer's smoking-cessation treatment Chantix might not increase the risk of heart attack and other serious heart conditions, as was reported in a 2011 study, according to a review that looked at data on 9,232 people treated for three months. Researcher Judith Prochaska said the first study was misleading because "findings were inflated, and they were just focusing on that relative risk." Only 0.63% of 5,431 individuals developed a serious heart problem.

View Full Article in:

Review finds Chantix may not raise heart risks - Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD